Patients with RA who use abatacept mount little humoral or cell-mediated responses to the recombinant zoster vaccine, with more injection-site reactions but similar RA flare rates compared with ...

"Real-world" data from the Swedish Rheumatology Quality register show that patients with rheumatoid arthritis (RA) for whom abatacept (Orencia, Bristol-Myers Squibb) is the first biologic ...

The risk or severity of infection can be increased when Adalimumab is combined with Abatacept. The risk or severity of adverse effects can be increased when Abatacept is combined with Bacillus ...

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a ...

Advantage plans do a better job than standalone Part D policies, albeit with important gap ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SAN DIEGO — COVID-19 vaccine boosters led to a ...

Please provide your email address to receive an email when new articles are posted on . A recent study on the benefits of abatacept for patients with moderate-to-severe Crohn’s disease or ulcerative ...

Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website -- FootballMatcher.com -- to help people connect for pickup games. The fun went on pause when Day ...

Efficacy and Safety Data Further Supporting Use of ORENCIA in New-to-Biologic Patients with Moderate to Severe Rheumatoid Arthritis Added to Product Labeling NEW YORK--(BUSINESS WIRE)--Bristol-Myers ...

Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell costimulation modulator, in ...

Review the side-effects of Abatacept as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who ...